JP2024533601A - 神経保護剤としての一酸化窒素放出プロスタミド - Google Patents

神経保護剤としての一酸化窒素放出プロスタミド Download PDF

Info

Publication number
JP2024533601A
JP2024533601A JP2024517091A JP2024517091A JP2024533601A JP 2024533601 A JP2024533601 A JP 2024533601A JP 2024517091 A JP2024517091 A JP 2024517091A JP 2024517091 A JP2024517091 A JP 2024517091A JP 2024533601 A JP2024533601 A JP 2024533601A
Authority
JP
Japan
Prior art keywords
dihydroxycyclopentyl
propen
phenylethyl
hepten
ethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533601A5 (https=
Inventor
インパグナッティエッロ，フランチェスコ
バスティア，エレナ
Original Assignee
ニコックス エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニコックス エス．エー． filed Critical ニコックス エス．エー．
Publication of JP2024533601A publication Critical patent/JP2024533601A/ja
Publication of JP2024533601A5 publication Critical patent/JP2024533601A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024517091A 2021-09-20 2021-09-20 神経保護剤としての一酸化窒素放出プロスタミド Pending JP2024533601A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/075786 WO2023041182A1 (en) 2021-09-20 2021-09-20 Nitric oxide releasing prostamide as neuroprotective agent

Publications (2)

Publication Number Publication Date
JP2024533601A true JP2024533601A (ja) 2024-09-12
JP2024533601A5 JP2024533601A5 (https=) 2024-09-20

Family

ID=77998957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517091A Pending JP2024533601A (ja) 2021-09-20 2021-09-20 神経保護剤としての一酸化窒素放出プロスタミド

Country Status (7)

Country Link
US (1) US20240390390A1 (https=)
EP (1) EP4404936A1 (https=)
JP (1) JP2024533601A (https=)
CN (1) CN117979973A (https=)
CA (1) CA3232002A1 (https=)
TW (1) TW202327617A (https=)
WO (1) WO2023041182A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020011955A (ja) * 2018-07-12 2020-01-23 ニコックス エス．エー． 一酸化窒素放出プロスタミドを含有する眼科用組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AR076731A1 (es) 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
US11058691B2 (en) 2016-11-08 2021-07-13 Nicox S.A. Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma
ES2923623T3 (es) 2018-02-21 2022-09-29 Nicox Sa Procedimiento para la preparación de un análogo de prostaglandina donante de óxido nítrico

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020011955A (ja) * 2018-07-12 2020-01-23 ニコックス エス．エー． 一酸化窒素放出プロスタミドを含有する眼科用組成物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADV. THER., vol. 23, no. 3, JPN6025033747, 2006, pages 385 - 394, ISSN: 0005666817 *
CLIN. OPHTHALMOL., vol. 6, JPN6025033748, 2012, pages 1547 - 1552, ISSN: 0005666818 *
EXP. EYE RES., vol. 93, JPN6026007526, 2011, pages 265 - 270, ISSN: 0005808620 *
IOVS, vol. 56, no. 11, JPN6025033749, 2015, pages 6558 - 6564, ISSN: 0005666819 *
J. NEUROCHEM., vol. 76, JPN6026007522, 2001, pages 1233 - 1241, ISSN: 0005808618 *
日眼会誌, vol. 101巻8号, JPN6026007521, 1997, pages 639 - 643, ISSN: 0005808617 *
日眼会誌, vol. 115巻3号, JPN6026007524, 2011, pages 213 - 237, ISSN: 0005808619 *

Also Published As

Publication number Publication date
CN117979973A (zh) 2024-05-03
WO2023041182A1 (en) 2023-03-23
TW202327617A (zh) 2023-07-16
US20240390390A1 (en) 2024-11-28
CA3232002A1 (en) 2023-03-23
EP4404936A1 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
Casson Medical therapy for glaucoma: A review
US6316441B1 (en) Brinzolamide and brimonidine for treating glaucoma
JP2011516537A (ja) 安定性のある眼科用の製剤
JP2021046394A (ja) ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物
Egorov et al. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma
US20150099807A1 (en) Preservative free bimatoprost solutions
JP6820847B2 (ja) プロスタグランジンと一酸化窒素供与体との組み合わせ
Sakai et al. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients
US20030007971A1 (en) Remedies for ophthalmic diseases
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
JP2024533601A (ja) 神経保護剤としての一酸化窒素放出プロスタミド
HK40109915A (zh) 作为神经保护剂的释放一氧化氮的前列腺酰胺
KR20230147006A (ko) 무방부제 안과용 약학 에멀젼 및 이의 적용
Khan et al. Beyond the local effect: an examination of cardiovascular and other systemic complications of ophthalmologic drugs
Stewart Review timolol hemihydrate: A new formulation of Timolol for the treatment of glaucoma
EP4233867B1 (en) Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy
Sharpe et al. A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost
CA2398900A1 (en) Therapeutic agents for opthalmopathy
WO2025090106A1 (en) Compositions and methods for treating neural degeneration in glaucoma and related conditions
AU2024366119A1 (en) Compositions and methods for treating neural degeneration in glaucoma and related conditions
Kanner et al. Adrenergic Agents
Lodhi et al. Latanoprost 0.005% v/s timolol maleate 0.5% pressure lowering effect in primary open angle glaucoma
Marc et al. Ocular toxicity of topical indomethacin eye drops
CN110496130A (zh) 一种防治糖尿病性视网膜病变的药物组合物
HK1241269B (zh) 前列腺素类和一氧化氮供体的组合产品

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303